Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Shisong is an Oxford University researcher in the Department of Oncology, and the CTO of Oxford Vacmedix, which has developed a technique to grow overlapping peptides in bacteria, to use for cellular immunity vaccines.

Oxford Vacmedix has raised almost £1 million in funding, and is now looking to raise a second round of around £10 million.  There are two centers, one in Oxford and one in China, working on this technology.

Q: What is your background?  Why are you doing this?
A: I studied medicine in China, and then came to London and Harvard for my PhD and initial post doc post.  I had been involved in immunology in London and the US, and was working on HIV and peptide segments for vaccines when I came to Oxford.  I started looking into ways of producing these overlapping peptide segments, and starting using bacteria as a cheap method.

Read more (Enterprising Oxford website)

Similar stories

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Alan Davidson Foundation supports ground-breaking Motor Neurone Disease research

A £210,000 donation from the Alan Davidson Foundation (ADF) has been made to the Nuffield Department of Clinical Neurosciences (NDCN) to advance the University’s world leading research into Motor Neurone Disease (MND). The funding will support a project manager for three years to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis and eventually, prevention of all forms of MND.

New Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease

GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Oxford joins consortium to advance quantum drug discovery with £6.8M grant from Innovate UK

Oxford University today joins a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA.

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.